North America Bipolar Disorder Market

North America Bipolar Disorder Market Size (2024 to 2029)

The size of the Bipolar Disorder Market in North America was valued at around USD 2.66 billion in 2024 and is estimated to grow at a CAGR of 2.45% to reach USD 3.01 billion by 2029. 

A person with the disorder deals with drastic mood swings from high mania to extreme lows(depression). Bipolar disorder was once referred to as a manic depression. It is to be treated for a lifetime.

Disasters such as pandemic always lead to more psychological casualties than physical. COVID- 19 pandemic has strongly impacted the mental health issues. It has created a lot of uncertainty for individuals with Bipolar Disorder. The pandemic certainly preponed the growth of the North American Bipolar disorder market. The rise in awareness programs and increased drug productions drive up the Bipolar disorder market in North America.

Accessibility of treatment options and technological advancements that encourage the exact exposure of the patient’s mood and mental state impels the market growth. Innovations in technology lead to the integration of drugs, and therapies are propelling market growth. 2.8% of the adults in the US are diagnosed with bipolar disorder, and 4.4% have undergone at some point in their lives, according to the National Institute of Mental Health (NIMH). The existence of a well-developed hospital and diagnostic center network, high rate of diagnosis, transparent process for profitable reimbursements, and great attention to research and development are fueling the growth in the region. With the surge in healthcare expenditure, the US spends around 3.2$ trillion or 17% of the GDP and serves the best infrastructure and solutions in technology for the patients in this region.

The main problem that currently restricts market growth is a lack of proper facilities to diagnose the disorder. Lack of widespread awareness and strict government rules on misdiagnosis and inadequate technology causes the disorder to be considered another personality disorder or depression. Series competition to manufacture bipolar disorder drugs tends to impact on Bipolar disorder market. However, side effects caused by the drugs and misdiagnosis of the disease tend to restrict the market's growth.

This research report on the North America Bipolar Disorder Market has been segmented and sub-segmented into the following categories.

North America Bipolar Disorder Market Analysis By Type

• Bipolar I Disorder
• Bipolar II Disorder
• Cyclothymic Disorder

North America Bipolar Disorder Market Analysis By Mechanism of Action

• Monoamine Oxidase Inhibitors
• Tricyclic Antidepressants
• Benzodiazepines
• Serotonin-norepinephrine Reuptake Inhibitors
• Beta-Blockers
• Selective Serotonin Reuptake Inhibitors
• Others

North America Bipolar Disorder Market Analysis By Drug Class

• Antianxiety Drugs
• Mood Stabilizers
• Antidepressant Drugs
• Antipsychotic Drugs
• Anticonvulsants

North America Bipolar Disorder Market Analysis By Country

• The United States
• Canada
• Rest of North America

Regionally, North America is predicted to rule the global bipolar disorder market during the forecast period due to various government projects and campaigns to create awareness, leading to a surge in the bipolar disorder market in North America.

High-stress levels, Y-O-Y growth in the incidence of bipolar disorders, and inadequate sleep, and the tendency of substance abuse among the people are fuelling the market growth in the region.The United States market is anticipated to dominate the bipolar disorder market in the region. It is accounted to have 80% of the share alone in North America due to the existence of better healthcare infrastructure. 1 in 5 adults undergoes mental ailments in a year in the US, according to a report published by the National Alliance on Mental Illness. The increasing number of mergers and acquisitions among drug manufacturing companies is a key factor stimulating bipolar disorder in the region.Canada is right next to the U.S. and the second most promising region in the North American market due to an increase in awareness regarding the diagnosis and treatment of bipolar disorders, and unsatisfied demands in treating disorders are some of the major factors escalating the market growth.

KEY MARKET PLAYERS

Major companies in the North America bipolar disorder market are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Ostuca Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc and AbbVie, Inc.